A review of the antitumour activity of vinorelbine in breast cancer
The use of vinorelbine 30 mg/m2/week as a single-agent treatment in advanced breast cancer has achieved response rates of > 20% as second-line treatment and 40 to 50% as first-line treatment. The major toxicity of the drug is reversible neutropenia; 35 to 50% of treated patients have grade IV neutropenia. The agent did not induce thrombocytopenia and proved mildly emetogenic and neurotoxic. Activity was confirmed in combination with fluorouracil or doxorubicin, when response rates ranging from 60 to 74% were achieved. Thus, vinorelbine appears to be a promising agent in the treatment of advanced breast cancer.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1992 |
|---|---|
| Erschienen: |
1992 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 Suppl 4 |
|---|---|
| Enthalten in: |
Drugs - 44 Suppl 4(1992) vom: 31., Seite 29-35; discussion 66-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marty, M [VerfasserIn] |
|---|
| Themen: |
5V9KLZ54CY |
|---|
| Anmerkungen: |
Date Completed 23.03.1993 Date Revised 30.11.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM01264353X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM01264353X | ||
| 003 | DE-627 | ||
| 005 | 20231221053154.0 | ||
| 007 | tu | ||
| 008 | 231221s1992 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0043.xml |
| 035 | |a (DE-627)NLM01264353X | ||
| 035 | |a (NLM)1283848 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Marty, M |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A review of the antitumour activity of vinorelbine in breast cancer |
| 264 | 1 | |c 1992 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 23.03.1993 | ||
| 500 | |a Date Revised 30.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The use of vinorelbine 30 mg/m2/week as a single-agent treatment in advanced breast cancer has achieved response rates of > 20% as second-line treatment and 40 to 50% as first-line treatment. The major toxicity of the drug is reversible neutropenia; 35 to 50% of treated patients have grade IV neutropenia. The agent did not induce thrombocytopenia and proved mildly emetogenic and neurotoxic. Activity was confirmed in combination with fluorouracil or doxorubicin, when response rates ranging from 60 to 74% were achieved. Thus, vinorelbine appears to be a promising agent in the treatment of advanced breast cancer | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Vinblastine |2 NLM | |
| 650 | 7 | |a 5V9KLZ54CY |2 NLM | |
| 650 | 7 | |a Vinorelbine |2 NLM | |
| 650 | 7 | |a Q6C979R91Y |2 NLM | |
| 700 | 1 | |a Extra, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Dieras, V |e verfasserin |4 aut | |
| 700 | 1 | |a Giacchetti, S |e verfasserin |4 aut | |
| 700 | 1 | |a Ohana, S |e verfasserin |4 aut | |
| 700 | 1 | |a Espié, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs |d 1976 |g 44 Suppl 4(1992) vom: 31., Seite 29-35; discussion 66-9 |w (DE-627)NLM00001611X |x 1179-1950 |7 nnns |
| 773 | 1 | 8 | |g volume:44 Suppl 4 |g year:1992 |g day:31 |g pages:29-35; discussion 66-9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 Suppl 4 |j 1992 |b 31 |h 29-35; discussion 66-9 | ||